Publications by authors named "David Ungar"

Claim this Profile
L
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
Juan P Alderuccio, Weiyun Z Ai, John Radford, Melhem Solh, Kirit M Ardeshna, David Ungar

Blood Adv· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Alexander Spira, Xiaolei Zhou, Lei Chen, Ari Gnanasakthy, Luqiang Wang, David Ungar

Clin Lymphoma Myeloma Leuk· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
Brian Hess, William Townsend, Weiyun Ai, Anastasios Stathis, Melhem Solh, David Ungar

AAPS J· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, David Ungar

Lancet Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F Caimi, Erin Reid, David Ungar

Blood· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
Nitin Jain, Wendy Stock, Amer Zeidan, Ehab Atallah, James McCloskey, David Ungar

Blood Adv· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Brad S Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, David Ungar

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epstein Barr virus induced lymphoma in a child with IPEX syndrome.
Kenneth G Lucas, David Ungar, Melanie Comito, Brandt Groh

Pediatr Blood Cancer· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involving children with cancer in decision-making about research participation.
Steven Joffe, Conrad V Fernandez, Rebecca D Pentz, David R Ungar, N Ajoy Mathew

J Pediatr· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Children are not small adults: documentation of assent for research involving children.
David Ungar, Steven Joffe, Eric Kodish

J Pediatr· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synovial chondromatosis of the subtalar joint and tenosynovial chondromatosis of the posterior ankle.
Phi Van, Peter M Wilusz, David S Ungar, Guy R Pupp

J Am Podiatr Med Assoc· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis